Prior to joining the company, Dr. Girardet served as Vice President, Pharmaceutical and Translational Sciences at Ardea Biosciences, a member of the AstraZeneca Group, where he led the progression of Ardea's internal discovery programs from concept to clinical development, and eventually to approval. He led the CMC teams through all clinical phases, NDA preparation, and the review and FDA approval of Zurampic® and Duzallo®, for which he was also heavily involved in launch preparation. In addition, Dr. Girardet assisted the business development group in the sale of Ardea Biosciences to AstraZeneca, and in the successful licensing of refametinib to Bayer Healthcare. He supervised Ardea's GMP productions during clinical trials of refametinib, lesinurad, and verinurad.


Previously, Dr. Girardet was Senior Director, Discovery Logistics, at Ardea Biosciences where he managed all of Ardea's drug substance GMP production and directed the intellectual property team to secure the company's assets. Earlier in his career, Dr. Girardet held positions of increasing responsibility at Valeant Pharmaceuticals, Ribapharm, and ICN Pharmaceuticals.


Dr. Girardet completed a Postdoctoral Fellowship in the laboratory of Professor Leroy B. Townsend at the University of Michigan in Ann Arbor, Michigan, and he received a Ph.D. in chemistry and a B.S. in chemistry and biochemistry from the University of Montpellier, France. He has co-authored more than 45 peer-reviewed publications and book chapters, and is an inventor on more than 30 U.S. patents.